NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

EXEL

Exelixis Inc

May 16 • 04:00PM ET

45.40

Dollar change -0.86
Percentage change -1.86	%

Healthcare • Biotechnology • USA • NASD

Peers: REGN AMGN GILD VRTX BIIB BMRN INCY ALNY NBIX IONS

| Held by: IJH VTI VB VXF VBK XBI MDY XMHQ IBB IJK

Scroll to Statements

Index	-	P/E	20.60	EPS (ttm)	2.20	Insider Own	3.32%	Shs Outstand	275.03M	Perf Week	25.52%
Market Cap	12.38B	Forward P/E	15.88	EPS next Y	2.86	Insider Trans	-8.20%	Shs Float	263.67M	Perf Month	25.59%
Income	643.57M	PEG	0.71	EPS next Q	0.60	Inst Own	94.46%	Short Float	7.28%	Perf Quarter	29.71%
Sales	2.30B	P/S	5.39	EPS this Y	40.40%	Inst Trans	2.79%	Short Ratio	6.58	Perf Half Y	26.64%
Book/sh	7.75	P/B	5.86	EPS next Y	15.67%	ROA	22.82%	Short Interest	19.18M	Perf Year	116.29%
Cash/sh	3.78	P/C	12.00	EPS next 5Y	29.08%	ROE	30.22%	52W Range	20.14 - 48.85	Perf YTD	36.34%
Dividend Est.	-	P/FCF	15.08	EPS past 5Y	11.55%	ROI	27.76%	52W High	-7.06%	Beta	0.32
Dividend TTM	-	Quick Ratio	3.44	Sales past 5Y	18.34%	Gross Margin	96.78%	52W Low	125.42%	ATR (14)	1.98
Dividend Ex-Date	-	Current Ratio	3.50	EPS Y/Y TTM	244.87%	Oper. Margin	35.43%	RSI (14)	73.08	Volatility	6.24% 3.93%
Employees	1147	Debt/Eq	0.09	Sales Y/Y TTM	24.49%	Profit Margin	27.99%	Recom	1.95	Target Price	40.89
Option/Short	Yes / Yes	LT Debt/Eq	0.09	EPS Q/Q	353.64%	Payout	0.00%	Rel Volume	1.88	Prev Close	46.26
Sales Surprise	11.18%	EPS Surprise	70.89%	Sales Q/Q	30.62%	Earnings	May 13 AMC	Avg Volume	2.92M	Price	45.40
SMA20	17.23%	SMA50	21.34%	SMA200	38.21%	Trades		Volume	5,489,151	Change	-1.86%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-24-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$36
Jan-27-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$30 → $40
Jan-24-25	Downgrade	Oppenheimer	Outperform → Perform
Dec-20-24	Downgrade	BMO Capital Markets	Outperform → Market Perform	$36 → $40
Dec-17-24	Downgrade	BofA Securities	Buy → Neutral	$35 → $39
Oct-16-24	Reiterated	RBC Capital Mkts	Outperform	$30 → $34
Sep-19-24	Initiated	UBS	Neutral	$30
Apr-11-24	Downgrade	Barclays	Overweight → Equal Weight	$25
Dec-19-23	Initiated	BTIG Research	Buy	$27
Dec-15-23	Initiated	Citigroup	Buy	$31
Sep-26-23	Initiated	H.C. Wainwright	Buy	$28
Aug-22-23	Reiterated	Oppenheimer	Outperform	$25 → $29
Aug-08-23	Initiated	SVB Securities	Market Perform	$18
Jul-11-23	Resumed	Morgan Stanley	Equal-Weight	$21
May-10-23	Resumed	Piper Sandler	Overweight	$28
Mar-09-23	Initiated	Wells Fargo	Overweight	$23
Jan-26-23	Initiated	Credit Suisse	Outperform	$29
Oct-18-22	Initiated	JMP Securities	Mkt Outperform	$26
Jun-24-22	Initiated	BMO Capital Markets	Outperform	$28
Nov-19-21	Initiated	Piper Sandler	Overweight	$34

Show Previous Ratings

May-15-25 09:45AM	Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term (Zacks)
09:42AM	Company News for May 15, 2025 (Zacks)
May-14-25 07:56PM	Why Exelixis, Inc. (EXEL) Skyrocketed On Wednesday (Insider Monkey) +20.84%
04:42PM	These Stocks Moved the Most Today: Nvidia, AMD, Super Micro, UnitedHealth, eToro, Oklo, Exelixis, and More (Barrons.com)
03:05PM	These Stocks Are Moving the Most Today: Nvidia, AMD, Super Micro, UnitedHealth, eToro, Oklo, Exelixis, and More (Barrons.com)
02:22PM	Loading…
02:22PM	eToro's Nasdaq debut, Exelixis outlook, SepternaNovo deal (Yahoo Finance Video)
11:33AM	Why Exelixis Stock Is Skyrocketing Today (Motley Fool)
09:00AM	EXEL Q1 Earnings Beat, 2025 Sales View Up as Cabometyx Drives Top Line (Zacks)
08:40AM	Q1 2025 Exelixis Inc Earnings Call (Thomson Reuters StreetEvents)
03:18AM	Exelixis Inc (EXEL) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
May-13-25 06:06PM	Invenra Highlights Exelixis' Initiation of Phase 1 Clinical Study Evaluating XB628, a First-in-Class Bispecific Antibody in Participants with Recurrent Advanced or Metastatic Solid Tumors (Business Wire)
06:00PM	Exelixis (EXEL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:20PM	Exelixis (EXEL) Surpasses Q1 Earnings and Revenue Estimates (Zacks)
04:23PM	Exelixis: Q1 Earnings Snapshot (Associated Press Finance)
04:19PM	Biotech Leader Exelixis Pops After Obliterating First-Quarter Profit Expectations (Investor's Business Daily)
04:07PM	Loading…
04:07PM	Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate Update (Business Wire)
May-12-25 12:10PM	Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report? (Zacks)
09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
09:15AM	Urogen Pharma (URGN) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-11-25 04:52PM	Is Exelixis, Inc. (EXEL) One of the Best Stocks to Buy According to Jim Simons' Renaissance Technologies? (Insider Monkey)
May-08-25 05:10PM	Celldex Therapeutics (CLDX) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
09:15AM	Ahead of Exelixis (EXEL) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics (Zacks)
May-07-25 04:05PM	Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May (Business Wire)
May-03-25 02:47PM	Exelixis, Inc. (EXEL): Among the Large-Cap Stocks Insiders and Short Sellers Are Dumping Like Crazy (Insider Monkey)
May-02-25 09:50AM	Here's Why Exelixis (EXEL) is a Strong Momentum Stock (Zacks)
Apr-29-25 04:05PM	Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025 (Business Wire)
09:45AM	Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
06:42AM	Can Amgen Keep the Beat Streak Alive This Earnings Season? (Zacks)
Apr-26-25 08:00AM	MercadoLibre, The Amazon Of Latin America, Leads Five Stocks Near Buy Points (Investor's Business Daily)
Apr-25-25 01:29PM	Exelixis' Q1 Earnings: Will Cabometyx Maintain Momentum? (Zacks)
10:02AM	Loading…
Apr-24-25 10:02AM	Earnings Preview: Alkermes (ALKS) Q1 Earnings Expected to Decline (Zacks)
09:40AM	Here's Why Exelixis (EXEL) is a Strong Value Stock (Zacks)
Apr-22-25 10:01AM	Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Q1 Release (Zacks)
Apr-20-25 11:28AM	IDNA: The Cutting Edge Of Medical Science Is A Risky Investment (Seeking Alpha)
Apr-16-25 09:50AM	Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term (Zacks)
06:20AM	Is First Trust Mid Cap Core AlphaDEX ETF (FNX) a Strong ETF Right Now? (Zacks)
Apr-14-25 06:20AM	Should First Trust Mid Cap Core AlphaDEX ETF (FNX) Be on Your Investing Radar? (Zacks)
Apr-11-25 12:10PM	Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report? (Zacks)
09:45AM	Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio (Zacks)
Apr-10-25 03:30PM	Harbor Mid Cap Value Fund Q4 2024 Commentary (Seeking Alpha)
06:20AM	Should John Hancock Multifactor Small Cap ETF (JHSC) Be on Your Investing Radar? (Zacks)
Apr-08-25 09:40AM	Why Exelixis (EXEL) is a Top Value Stock for the Long-Term (Zacks)
Apr-07-25 06:20AM	Is John Hancock Multifactor Small Cap ETF (JHSC) a Strong ETF Right Now? (Zacks)
Apr-03-25 06:15AM	The Smartest Biotech Stocks to Buy With $50 (Motley Fool)
Apr-02-25 03:00PM	Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More (Zacks)
09:48AM	Is Exelixis, Inc. (EXEL) The Most Profitable Biotech Stock To Buy Right Now? (Insider Monkey)
Mar-31-25 07:05PM	Orchestra BioMed Holdings, Inc. (OBIO) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
Mar-30-25 03:50AM	abrdn Life Sciences Investors Q4 2024 Commentary (Seeking Alpha)
02:50AM	abrdn Healthcare Investors Q4 2024 Commentary (Seeking Alpha)
Mar-27-25 03:00PM	FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors (Zacks)
11:05AM	Exelixis cabozantinib approval certainly positive, says Citi (TipRanks)
07:07AM	US FDA approves Exelixis' Cabometyx for advanced neuroendocrine tumours (Pharmaceutical Business Review)
Mar-26-25 05:20PM	Exelixis to present positive preclinical data across pipeline portfolio at AACR (TipRanks)
03:00PM	Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold? (Zacks)
09:45AM	Here's Why Exelixis (EXEL) is a Strong Growth Stock (Zacks)
09:15AM	Exelixis Announces U.S. FDA Approval of CABOMETYX (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors (Business Wire)
Mar-25-25 05:15PM	Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025 (Business Wire)
Mar-24-25 10:57AM	Biotech Leader Exelixis Eyes Buy Point In Monday's Stock Market Rally (Investor's Business Daily)
Mar-21-25 11:30AM	Exact Sciences (EXAS) Down 10.6% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-20-25 12:30PM	Still Feeling Bearish? Best Defensive Stocks To Buy Now (SeekingAlpha)
11:20AM	Defensive Stocks For Unpredictable Trump Policy (SeekingAlpha)
09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Mar-19-25 07:09AM	Exelixis Growth Continues with Big Money Boosts (FX Empire)
Mar-18-25 05:30AM	Exelixis, Inc. (EXEL): Among the Best Biotech Stocks to Buy According to Billionaires (Insider Monkey)
Mar-13-25 11:30AM	Exelixis (EXEL) Up 13.4% Since Last Earnings Report: Can It Continue? (Zacks)
Mar-08-25 07:33AM	Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge (PR Newswire)
Mar-01-25 02:38PM	Is Exelixis, Inc. (EXEL) The Best Immunology Stock To Buy Now? (Insider Monkey)
Feb-28-25 04:33AM	Exelixis focuses on future growth despite COSMIC-313 trial challenges (Pharmaceutical Technology)
Feb-25-25 04:05PM	Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in March (Business Wire)
03:11PM	Analysts Give The Green Light To Two Stocks With Brighter Outlook Than Even Nvidia (Investor's Business Daily)
Feb-23-25 01:16PM	Exelixis, Inc. (EXEL): Among Renaissance Technologies Portfolios Top Stock Picks (Insider Monkey)
Feb-21-25 06:31PM	Why Exelixis Stock Trounced the Market on Thursday (Motley Fool) +5.02%
01:30PM	Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday? (Benzinga)
Feb-20-25 05:05PM	Exelixis Announces a Newly Authorized $500 Million Stock Repurchase Program (Business Wire)
12:45PM	Is Exelixis (EXEL) a Solid Growth Stock? 3 Reasons to Think "Yes" (Zacks)
Feb-17-25 09:15AM	International Markets and Exelixis (EXEL): A Deep Dive for Investors (Zacks)
08:19AM	Five-year results see Exelixis RCC therapy extending overall survival (Clinical Trials Arena)
Feb-15-25 11:10AM	Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX (cabozantinib) in Combination with Opdivo (nivolumab) in Patients with Advanced Kidney Cancer at ASCO GU 2025 (Business Wire)
Feb-14-25 09:40AM	Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy? (Zacks)
Feb-13-25 04:05PM	Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit (Business Wire) +5.15%
Feb-12-25 02:13AM	Exelixis Inc (EXEL) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Feb-11-25 10:15PM	Exelixis (EXEL) Q4 2024 Earnings Call Transcript (Motley Fool)
06:00PM	Exelixis (EXEL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:25PM	Exelixis (EXEL) Q4 Earnings and Revenues Top Estimates (Zacks)
04:22PM	Exelixis: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Exelixis Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Corporate Update (Business Wire)
Feb-10-25 09:00AM	2 Stocks to Buy With Less Than $40 (Motley Fool)
Feb-07-25 05:00AM	The 10 best stocks of the last decade (Quartz)
Feb-06-25 09:15AM	Curious about Exelixis (EXEL) Q4 Performance? Explore Wall Street Estimates for Key Metrics (Zacks)
Jan-29-25 09:40AM	Here's Why Exelixis (EXEL) is a Strong Value Stock (Zacks)
Jan-28-25 04:05PM	Exelixis to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025 (Business Wire)
10:00AM	Exelixis (EXEL) Earnings Expected to Grow: Should You Buy? (Zacks)
Jan-25-25 10:00AM	Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-001 Trial Evaluating Zanzalintinib Alone or in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer at ASCO GI 2025 (Business Wire)
Jan-24-25 02:30PM	Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented at ASCO GI 2025 (Business Wire) -5.13%
01:37PM	Exelixis Stock Faces a Reality Check: Will It Hit $41 or Drop to $33? (GuruFocus.com)
11:17AM	Exelixis Stock Falls as Oppenheimer Downgrades Over Drug Differentiation Concerns (GuruFocus.com)
Jan-22-25 07:44AM	Revenues, Treatment Pipeline Driving Exelixis Higher (FX Empire) -9.74%
Jan-21-25 09:32AM	What Makes Exelixis (EXEL) an Investment Bet? (Insider Monkey)
Jan-15-25 03:44PM	BeiGene Stock Meets 80-Plus RS Rating Benchmark (Investor's Business Daily)
Jan-14-25 03:30PM	BridgeBio Pharma Stock Earns 87 RS Rating (Investor's Business Daily)

Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
POSTE GEORGE	Director	May 16 '25	Option Exercise	19.77	20,634	407,934	189,654	May 16 08:58 PM
POSTE GEORGE	Director	May 16 '25	Sale	45.99	20,634	948,958	169,020	May 16 08:58 PM
Senner Christopher J.	EVP and CFO	May 16 '25	Option Exercise	18.80	100,000	1,880,000	1,067,842	May 16 08:58 PM
Senner Christopher J.	EVP and CFO	May 16 '25	Sale	46.00	100,000	4,600,000	967,842	May 16 08:58 PM
PAPADOPOULOS STELIOS	Director	May 15 '25	Option Exercise	20.09	36,508	733,351	1,300,050	May 16 08:57 PM
PAPADOPOULOS STELIOS	Director	May 15 '25	Sale	44.35	36,508	1,619,130	1,279,416	May 16 08:57 PM
MORRISSEY MICHAEL	President and CEO	May 14 '25	Option Exercise	18.80	308,365	5,797,262	1,931,374	May 16 08:57 PM
Hessekiel Jeffrey	EVP & General Counsel	May 15 '25	Sale	46.18	25,000	1,154,500	693,396	May 16 08:57 PM
Haley Patrick J.	EVP, Commercial	May 15 '25	Option Exercise	18.80	116,383	2,188,000	562,842	May 16 08:57 PM
Haley Patrick J.	EVP, Commercial	May 15 '25	Sale	47.96	126,383	6,061,703	446,459	May 16 08:57 PM
Haley Patrick J.	EVP, Commercial	May 14 '25	Sale	42.68	10,000	426,800	491,164	May 16 08:57 PM
Peterson Amy C.	EVP Prod Dev & Med Aff & CMO	May 16 '25	Option Exercise	21.75	40,000	870,000	538,169	May 16 08:57 PM
Peterson Amy C.	EVP Prod Dev & Med Aff & CMO	May 16 '25	Sale	45.47	72,776	3,309,125	465,393	May 16 08:57 PM
AMY PETERSON	Officer	May 16 '25	Proposed Sale	46.26	72,776	3,366,618		May 16 04:11 PM
CHRISTOPHER J SENNER	Officer	May 16 '25	Proposed Sale	46.00	100,000	4,600,000		May 16 04:09 PM
GEORGE POSTE	Director	May 16 '25	Proposed Sale	45.99	20,634	948,958		May 16 04:09 PM
STELIOS PAPADOPOULOS	Director	May 15 '25	Proposed Sale	44.35	36,508	1,619,130		May 15 06:00 PM
PATRICK JOSEPH HALEY	Officer	May 15 '25	Proposed Sale	48.05	116,383	5,592,739		May 15 05:09 PM
JEFFREY J HESSEKIEL	Officer	May 15 '25	Proposed Sale	46.18	25,000	1,154,610		May 15 04:29 PM
PATRICK JOSEPH HALEY	Officer	May 15 '25	Proposed Sale	46.95	10,000	469,500		May 15 04:05 PM
PATRICK JOSEPH HALEY	Officer	May 14 '25	Proposed Sale	42.68	10,000	426,800		May 14 04:22 PM
Aftab Dana	CSO/EVP Disc & Trans Research	May 01 '25	Sale	39.00	1,508	58,812	693,181	May 05 07:12 PM
DANA T AFTAB	Officer	May 01 '25	Proposed Sale	39.00	1,508	58,812		May 01 04:02 PM
Haley Patrick J.	EVP, Commercial	Mar 03 '25	Sale	38.80	10,000	388,000	341,028	Mar 05 08:47 PM
PATRICK JOSEPH HALEY	Officer	Mar 03 '25	Proposed Sale	38.80	10,000	388,000		Mar 03 04:18 PM
Smith Julie	Director	Feb 27 '25	Option Exercise	20.19	54,514	1,100,494	65,292	Feb 28 08:35 PM
Smith Julie	Director	Feb 28 '25	Option Exercise	19.77	19,294	381,442	30,072	Feb 28 08:35 PM
Smith Julie	Director	Feb 27 '25	Sale	38.13	54,514	2,078,619	10,778	Feb 28 08:35 PM
Smith Julie	Director	Feb 28 '25	Sale	37.62	19,294	725,840	10,778	Feb 28 08:35 PM
WYSZOMIERSKI JACK L	Director	Feb 28 '25	Option Exercise	20.50	15,874	325,417	365,373	Feb 28 08:34 PM
WYSZOMIERSKI JACK L	Director	Feb 28 '25	Sale	37.80	8,768	331,430	356,605	Feb 28 08:34 PM
JACK L WYSZOMIERSKI	Director	Feb 28 '25	Proposed Sale	37.80	8,768	331,394		Feb 28 04:05 PM
Smith Julie	Director	Feb 27 '25	Proposed Sale	37.13	73,808	2,740,491		Feb 27 05:12 PM
Haley Patrick J.	EVP, Commercial	Feb 24 '25	Sale	36.98	52,636	1,946,479	303,310	Feb 26 08:01 PM
Oliver Bob	Director	Feb 25 '25	Option Exercise	19.28	15,147	292,034	52,161	Feb 26 08:00 PM
Oliver Bob	Director	Feb 25 '25	Sale	37.25	18,647	694,601	33,514	Feb 26 08:00 PM
Aftab Dana	CSO/EVP Disc & Trans Research	Feb 24 '25	Sale	36.75	26,987	991,772	511,908	Feb 26 08:00 PM
Senner Christopher J.	EVP and CFO	Feb 24 '25	Option Exercise	18.80	29,314	551,103	808,921	Feb 26 08:00 PM
Senner Christopher J.	EVP and CFO	Feb 24 '25	Sale	36.14	29,314	1,059,408	779,607	Feb 26 08:00 PM
Oliver Bob	Director	Feb 25 '25	Proposed Sale	37.25	18,647	694,601		Feb 25 05:05 PM
Haley Patrick J.	Officer	Feb 24 '25	Proposed Sale	36.84	52,636	1,939,213		Feb 24 06:02 PM
Aftab Dana	Officer	Feb 24 '25	Proposed Sale	36.75	26,987	991,772		Feb 24 05:55 PM
Senner Christopher J.	Officer	Feb 24 '25	Proposed Sale	36.14	29,314	1,059,370		Feb 24 03:34 PM
Beckerle Mary C	Director	Feb 14 '25	Option Exercise	23.24	8,354	194,147	42,616	Feb 19 08:32 PM
Beckerle Mary C	Director	Feb 14 '25	Sale	34.88	12,210	425,878	30,406	Feb 19 08:32 PM
POSTE GEORGE	Director	Feb 14 '25	Option Exercise	20.50	15,874	325,417	184,894	Feb 19 08:32 PM
POSTE GEORGE	Director	Feb 14 '25	Sale	34.74	15,874	551,463	169,020	Feb 19 08:32 PM
Freire Maria C	Director	Feb 14 '25	Option Exercise	21.52	44,114	949,521	135,121	Feb 19 08:31 PM
Freire Maria C	Director	Feb 14 '25	Sale	34.94	44,114	1,541,343	91,007	Feb 19 08:31 PM
Eckhardt Sue Gail	Director	Feb 14 '25	Option Exercise	23.24	7,712	179,227	41,974	Feb 19 08:31 PM
Eckhardt Sue Gail	Director	Feb 14 '25	Sale	35.02	11,568	405,111	30,406	Feb 19 08:31 PM
Freire Maria C	Director	Feb 14 '25	Proposed Sale	34.94	44,114	1,541,207		Feb 14 05:59 PM
Beckerle Mary C	Director	Feb 14 '25	Proposed Sale	34.88	12,210	425,865		Feb 14 05:40 PM
POSTE GEORGE	Director	Feb 14 '25	Proposed Sale	34.74	15,874	551,431		Feb 14 05:36 PM
Eckhardt Sue Gail	Director	Feb 14 '25	Proposed Sale	34.37	11,568	397,592		Feb 14 04:20 PM
Hessekiel Jeffrey	EVP & General Counsel	Nov 27 '24	Option Exercise	18.80	129,314	2,431,103	644,967	Dec 02 08:29 PM
Hessekiel Jeffrey	EVP & General Counsel	Nov 29 '24	Sale	36.67	60,000	2,200,200	486,059	Dec 02 08:29 PM
JEFFREY HESSEKIEL	Officer	Nov 29 '24	Proposed Sale	36.67	60,000	2,200,230		Nov 29 01:12 PM
Haley Patrick J.	EVP, Commercial	Nov 22 '24	Sale	35.27	10,000	352,700	278,665	Nov 26 07:05 PM
PATRICK JOSEPH HALEY	Officer	Nov 22 '24	Proposed Sale	35.27	10,000	352,700		Nov 22 04:01 PM
Haley Patrick J.	EVP, Commercial	Nov 18 '24	Sale	34.36	41,588	1,428,822	288,665	Nov 19 08:03 PM
Haley Patrick J.	Officer	Nov 18 '24	Proposed Sale	34.41	19,381	666,974		Nov 18 06:50 PM
PATRICK JOSEPH HALEY	Officer	Nov 18 '24	Proposed Sale	34.31	22,207	761,884		Nov 18 04:10 PM
Aftab Dana	CSO/EVP Disc & Trans Research	Nov 05 '24	Option Exercise	18.80	96,986	1,823,337	595,931	Nov 07 07:44 PM
Aftab Dana	CSO/EVP Disc & Trans Research	Nov 05 '24	Sale	35.00	96,986	3,394,510	498,945	Nov 07 07:44 PM
Hessekiel Jeffrey	EVP & General Counsel	Nov 01 '24	Sale	34.13	50,000	1,706,500	530,325	Nov 05 07:05 PM
POSTE GEORGE	Director	Nov 01 '24	Sale	34.00	30,000	1,020,000	169,020	Nov 05 07:04 PM
DANA T AFTAB	Officer	Nov 05 '24	Proposed Sale	35.00	96,986	3,394,510		Nov 05 04:23 PM
Aftab Dana	CSO/EVP Disc & Trans Research	Oct 30 '24	Sale	31.40	1,162	36,487	498,945	Nov 01 06:43 PM
POSTE GEORGE	Director	Nov 01 '24	Proposed Sale	34.00	30,000	1,020,112		Nov 01 04:54 PM
JEFFREY J HESSEKIEL	Officer	Nov 01 '24	Proposed Sale	33.20	25,000	830,000		Nov 01 04:47 PM
Hessekiel Jeffrey	EVP & General Counsel	Oct 28 '24	Sale	28.39	25,000	709,750	580,325	Oct 30 06:04 PM
DANA T AFTAB	Officer	Oct 30 '24	Proposed Sale	31.40	1,162	36,487		Oct 30 04:10 PM
Haley Patrick J.	EVP, Commercial	Oct 02 '24	Option Exercise	24.41	100,000	2,441,000	441,036	Oct 03 09:22 PM
MORRISSEY MICHAEL	President and CEO	Oct 01 '24	Option Exercise	24.41	480,000	11,716,800	1,444,384	Oct 03 09:22 PM
Hessekiel Jeffrey	EVP & General Counsel	Sep 23 '24	Sale	26.38	25,000	659,500	605,325	Sep 25 07:32 PM
JEFFREY J HESSEKIEL	Officer	Sep 23 '24	Proposed Sale	26.42	75,000	1,981,500		Sep 23 04:24 PM
Hessekiel Jeffrey	EVP, General Counsel & Sec	Aug 26 '24	Option Exercise	24.41	20,000	488,200	650,325	Aug 28 07:07 PM
Hessekiel Jeffrey	EVP, General Counsel & Sec	Aug 26 '24	Sale	25.79	20,000	515,800	630,325	Aug 28 07:07 PM
Freire Maria C	Director	Aug 14 '24	Sale	26.56	8,250	219,120	91,007	Aug 16 07:35 PM
Aftab Dana	CSO/EVP Disc & Trans Research	Aug 12 '24	Sale	27.06	20,883	565,094	500,107	Aug 14 07:12 PM
MARIA C FREIRE	Director	Aug 14 '24	Proposed Sale	26.56	8,250	219,122		Aug 14 05:01 PM
POSTE GEORGE	Director	Aug 08 '24	Sale	26.89	33,725	906,865	199,020	Aug 12 07:22 PM
Aftab Dana	CSO/EVP Disc & Trans Research	Aug 07 '24	Option Exercise	24.41	95,000	2,318,950	615,990	Aug 09 07:32 PM
Aftab Dana	CSO/EVP Disc & Trans Research	Aug 07 '24	Sale	25.00	95,000	2,375,000	520,990	Aug 09 07:32 PM
Haley Patrick J.	EVP, Commercial	Aug 07 '24	Sale	25.50	14,000	357,000	341,036	Aug 09 07:32 PM
Hessekiel Jeffrey	EVP, General Counsel & Sec	Aug 07 '24	Option Exercise	24.41	80,000	1,952,800	710,325	Aug 09 07:32 PM
Hessekiel Jeffrey	EVP, General Counsel & Sec	Aug 07 '24	Sale	25.97	80,000	2,077,600	630,325	Aug 09 07:32 PM
Senner Christopher J.	EVP and CFO	Aug 09 '24	Option Exercise	24.41	125,000	3,051,250	846,680	Aug 09 07:31 PM
Senner Christopher J.	EVP and CFO	Aug 09 '24	Sale	27.19	125,000	3,398,750	721,680	Aug 09 07:31 PM
Senner Christopher J.	Officer	Aug 09 '24	Proposed Sale	27.17	125,000	3,396,250		Aug 09 05:20 PM
Aftab Dana	Officer	Aug 09 '24	Proposed Sale	27.25	20,883	569,062		Aug 09 05:18 PM
POSTE GEORGE	Director	Aug 08 '24	Proposed Sale	26.89	33,725	906,746		Aug 08 05:42 PM
DANA T AFTAB	Officer	Aug 07 '24	Proposed Sale	25.00	95,000	2,375,000		Aug 07 04:17 PM
JEFFREY J HESSEKIEL	Officer	Aug 07 '24	Proposed Sale	23.45	100,000	2,345,000		Aug 07 04:13 PM
PATRICK JOSEPH HALEY	Officer	Aug 07 '24	Proposed Sale	25.50	14,000	357,000		Aug 07 04:11 PM
WYSZOMIERSKI JACK L	Director	Jun 04 '24	Sale	22.00	8,287	182,314	349,499	Jun 06 08:37 PM
JOHNSON DAVID EDWARD	Director	May 30 '24	Buy	20.76	225,000	4,670,055	1,525,730	May 30 07:50 PM
JOHNSON DAVID EDWARD	Director	May 28 '24	Buy	20.32	200,000	4,063,900	1,300,730	May 30 07:50 PM
Smith Julie	Director	May 21 '24	Sale	21.12	27,280	576,154	5,445	May 23 06:55 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

EXEL

Exelixis Inc

Upgrade your FINVIZ experience